STEK Stemtech Corp
Wholesale-Drugs, Proprietaries & Druggists' Sundries · OTC · SEC CIK 1511820 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.9%
TTM net income YoY-18.7%
TTM EPS YoY100.0%
Revenue 3-yr CAGR-26.6%
Net income 3-yr CAGR—
Margins
Gross margin75.7%
Operating margin-134.0%
Net margin-191.3%
FCF margin-35.5%
EBITDA margin-124.8%
Returns
ROE—
ROA-102.2%
ROIC (approx.)—
Asset turnover0.53x
Leverage & solvency
Liabilities / assets361.0%
Debt / equity—
Current ratio0.05x
Interest coverage-2.62x
Cash quality & payout
Operating cash flow / net income0.19x
Accruals ratio-83.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.88M | $5.05M |
| Cost of revenue | $566,940 | $1.33M |
| Gross profit | $2.31M | $3.73M |
| R&D expense | $0 | $0 |
| SG&A expense | $4.55M | $5.23M |
| Operating income | -$2.71M | -$2.39M |
| Interest expense | $1.45M | $1.58M |
| Pretax income | -$4.05M | -$3.77M |
| Income tax | $0 | $0 |
| Net income | -$4.05M | -$3.77M |
| EBITDA | -$2.54M | -$2.04M |
| EPS (basic) | -0.02 | -0.03 |
| EPS (diluted) | -0.02 | -0.03 |
| Weighted avg. shares (diluted) | 169.82M | 118.70M |
| Balance sheet | ||
| Cash & equivalents | $238,245 | $255,298 |
| Inventory | $217,338 | $197,355 |
| Current assets | $457,062 | $921,746 |
| PP&E, net | $0 | $0 |
| Goodwill | $467,409 | $467,409 |
| Intangibles | $2.21M | $2.38M |
| Total assets | $3.15M | $3.78M |
| Current liabilities | $10.59M | $8.74M |
| Long-term debt | $4.16M | $3.82M |
| Total debt | $4.16M | $3.82M |
| Total liabilities | $10.59M | $8.74M |
| Shareholders' equity | -$6.96M | -$4.48M |
| Net debt | $3.92M | $3.56M |
| Shares outstanding | 425.98M | 135.76M |
| Cash flow statement | ||
| Operating cash flow | -$483,583 | -$601,198 |
| Capital expenditure | $0 | $0 |
| Free cash flow | -$483,583 | -$601,198 |
| Investing cash flow | $0 | $0 |
| Financing cash flow | $460,010 | $1.08M |
| Depreciation & amortization | $167,495 | $344,466 |
| Stock-based compensation | $439,054 | $440,256 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.